Investigational drug · Phase 2
HuL001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple Myeloma Refractory.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HuL001"
First trial start
2025
Aug 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HuL001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma Refractory
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HuL001" as an intervention, largest first.
- A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001Completed
HuniLife Biotechnology, Inc.Industry
NCT04540770 · 24 participants · Start Aug 31, 2021 · Primary completion Mar 4, 2022
Drug: HuL001 · For: Idiopathic Pulmonary Fibrosis
Sites: New Taipei City, Taiwan; Taipei, Taiwan
HuniLife Biotechnology, Inc.Industry
NCT07210047 · 21 participants (planned) · Start Aug 18, 2025 · Primary completion Nov 30, 2027
Drug: HuL001; Lenalidomide/Dexamethasone · For: Multiple Myeloma Refractory
Sites: Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- TGFβ Blockade by Inhibition of Enolase-1-Mediated Plasmin Targets Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma.
Chen ML, Chung IC, Huang KC, et al. · Oncol Res 2026
- Extracellular Enolase-1 Promotes CAF-Associated Stromal Reprogramming via the Plasmin/TGF-β Axis in Multiple Myeloma.
Chung IC, Chuang TY, Ko YT, et al. · Cancers (Basel) 2026
- Targeting ENO1 reprograms macrophage polarization to trigger antitumor immunity and improves the therapeutic effect of radiotherapy.
Lin YS, Chang HY, Hong WZ, et al. · Cell Death Dis 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.